




5th International
Workshop on
Waldenström's
Macroglobulinemia



Stockholm, Sweden
October 15-19, 2008

Acknowledgements

The 5th International Workshop on Waldenström's macroglobulinemia was made possible through the kind and generous unrestricted grants or gifts from the following sponsors:




**Peter and Helen Bing Fund for
Waldenström's Macroglobulinemia**

Karen Lee Sobol Foundation

**Bailey Family Foundation for
Waldenström's Macroglobulinemia**

**Linda and Edward Nelson Fund for
Waldenström's Macroglobulinemia**



Welcome to Stockholm, Sweden!

It is with great pleasure that we welcome you to Stockholm and the 5th International Workshop on Waldenström's Macroglobulinemia (IWWM5). The IWWM5 promises to be a very exciting meeting, and reflects the continued growth in investigators working on the genetic basis, pathogenesis, and treatment of WM. Since the IWWM began in 2000, the number of participating investigators has steadily grown, as have also the number of WM related publications including those arising from the IWWM which have been published in ***Blood, Clinical Lymphoma Myeloma, Haematologica, Journal of Clinical Oncology and Seminars in Oncology.***

We are particularly excited to host this workshop in the native land of Dr. Jan Waldenström, whose memorable career was marked by the recognition of several diseases, including the eponymous macroglobulinemia first described by him sixty-five years ago in ***Acta Medica Scandinavica***. As part of the IWWM5, a special tribute in honor of the life of Dr. Jan Waldenström will be hosted in the Nobel Hall of Stockholm City Hall.

We hope the IWWM5 will enrich each attendees understanding of Waldenström's Macroglobulinemia, and help foster discoveries leading to its cure.

Eva Kimby M.D., Ph.D.
Sweden

Steve Treon M.D., Ph.D.
USA



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Wednesday, October 15, 2008 Sheraton Stockholm
Registration and Welcome Dinner Reception

3:00-6:00 PM	Registration	Conference Hall Lobby
6:00 PM		Welcome Dinner
6:30 PM	Christopher Patterson (USA)	Program Review

Thursday, October 16, 2008 Sheraton Stockholm
Workshop Program

7:00-8:00 AM	Breakfast and Registration	Conference Hall Lobby
--------------	----------------------------	-----------------------

Session I Incidence and Predispositions to WM

Chairs: Dr. Björkholm (Sweden) and Dr. McMaster (USA)

8:00 AM	Dr. Wang (USA)	Trend and Geographical Variations of WM incidence in USA.
8:15 AM	Dr. Iwanaga (Japan)	Prevalence of MGUS and WM in Japan.
8:30 AM	Dr. Kyle (USA)	Natural History of IgM, MGUS and WM.
8:45 AM	Dr. Ögmundsdóttir (Iceland)	Familial predisposition to MGUS, MM, WM.
9:00 AM	Dr. McMaster (USA)	Precursor disorders in WM.
9:15 AM	Dr. Kristinsson (Sweden)	Risk lymphoproliferative disorders. in relatives of LPL patients.
9:30 AM	Dr. Hunter (USA)	Report from Familial Registry Studies in WM.
9:45 AM	Panel Discussion	All Session I Speakers.
10:15-10:30 AM		Session Break and Refreshments.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Session II Genetic Basis & Pathogenesis of WM and IgM Related Disorders

Chairs: Dr. Garcia-Sánchez (Spain) and Dr Pilarski (Canada)

10:30 AM	Dr. Pilarski (Canada)	Origin of malignant clone in WM.
10:45 AM	Dr. Sahota (England)	CD27 and defining B-cell memory origins in WM.
11:00 AM	Dr. Nguyen-Khac (France)	Cytogenetic abnormalities in untreated WM patients: Trisomy 4 prevalence.
11:15 AM	Dr. Eurelings (Netherlands)	Cytogenetic abnormalities in IgM Related Disorders.
11:30 AM	Dr. Braggio (USA)	TRAF3 abnormalities in WM.
11:45 AM	Panel Discussion	All Session II Speakers.
12:15-1:15 PM		Session Break and Lunch.

Session III Genetic Basis & Pathogenesis of WM and IgM Related Disorders

Chairs: Dr. Sahota (England) and Dr Ocio (Spain)

1:15 PM	Dr. Garcia-Sánchez (Spain)	Molecular characterizations of Ig rearrangements in WM.
1:30 PM	Dr. Adamia (USA)	MicroRNA studies in WM.
1:45 PM	Dr. Xu (USA)	Hypermethylation Studies of Tumor Suppressor Genes in WM.
2:00 PM	Dr. Ansell (USA)	Roles of CCL5 and IL6 in Biology of WM
2:15 PM	Dr. Giordano (USA)	Role of Hepatitis C in WM.
2:30 PM	Dr. Landgren (USA)	Chronic immune stimulation and subsequent WM.
2:45 PM	Panel Discussion	All Session III Speakers.
3:15-3:30 PM		Session Break and Refreshments.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Session IV Micro-environment and Immune Regulation in WM

Chairs: Dr. Joshua (Australia) and Dr. Munshi (USA)

3:30 PM	Dr. Hatjiharissi (Greece)	GEP of WM and Microenvironment
3:45 PM	Dr. Terpos (Greece)	Angiogenesis signaling in WM.
4:00 PM	Dr. Ocio (Spain)	Immunophenotypic comparisons of IgM, MGUS and WM.
4:15 PM	Dr. Munshi (USA)	Abnormal cytokine signaling in WM
4:30 PM	Dr. Joshua (Australia)	T-cell immunity in WM & MM.
4:45 PM	Panel Discussion	All Session IV Speakers.
5:15 PM	Dr. Kimby (Sweden) Dr. Treon (USA)	Day Summary and Adjournment.

Thursday, October 16, 2008

Vasa Museum

Opening Ceremonies

6:45 PM	Sheraton Stockholm	Buses depart to Vasa Museum.
7:00 PM	Vasa Museum	Welcome Reception and Tours.
8:00 PM	Dr. Kimby (Sweden)	Welcome Address.
8:00 PM	Dr. Treon (USA)	Welcome Address.
8:15 PM	J. May (USA)	IWMF President's Address.
8:30 PM	K. Lee Sobol (USA)	Special Guest, Author of "Twelve Weeks".
8:45 PM	Dr. Dunsire (USA)	President, CEO, Millennium Pharmaceuticals, Inc.
9:00 PM	S. Barer (USA)	Chair, CEO, Celgene Corporation.
9:15 PM	Dr. Kyle (USA)	Presentation of the Robert A. Kyle Award.
9:30 PM	Award Winner	Recipient Remarks.
10:30 PM	Vasa Museum	Buses depart to Sheraton Stockholm.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Friday, October 17, 2008 **Sheraton Stockholm**
Workshop Program

7:00-8:00 AM
Breakfast and Registration Conference Hall Lobby

Session V Prognostic, Predictive and Response Markers in WM
Chair: Dr. Owen (England) and Dr. Morel (France)

8:00 AM	Dr. Morel (France)	International WM Prognostic Index Project.
8:15 AM	Dr. Chang (Canada)	Role of 6q deletions as a prognostic marker in WM.
8:30 AM	Dr. Feuillard (France)	Plasma cell differentiation in indolent lymphomas originated from marginal zones.
8:45 AM	Dr. Kastiris (Greece)	Prognostication in young and elderly patients with WM.
9:00 AM	Dr. Owen (England)	Complexities of assessing response in WM.
9:15 AM	Dr. Yang (USA)	Soluble CD27 as a novel marker of disease in WM.
9:30 AM	Panel Discussion	All Session V Speakers.
10:00-10:15 AM		Session Break and Refreshments.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Session VI Treatment of Waldenström's Macroglobulinemia

Chairs: Dr. Morra (Italy) and Dr. Rohatiner (England)

10:15 AM	Dr. Dimopoulos (Greece)	Rituximab based therapies in WM.
10:30 AM	Dr. Ghielmini (Switzerland)	Maintenance Rituximab in indolent NHL.
10:45 AM	Dr. Morra (Italy)	Fludarabine based therapies in WM.
11:00 AM	Dr. Branagan (USA)	Long term outcomes of Fludarabine and Rituximab in WM.
11:15 AM	Dr. Chen (Canada)	Bortezomib in relapsed/refractory WM.
11:30 AM	Dr. Rohatiner (England)	Weekly versus twice weekly Bortezomib Combinations in WM.
11:45 AM	Dr. Treon (USA)	Primary Therapy of WM with Bortezomib based Therapy.
12:00 AM	Panel Discussion	All Session VI Speakers.
12:30-1:30 PM		Session Break and Lunch.
1:00 PM	Dr. O'Connor (USA)	<u>Special Guest Lecturer:</u> "The Emerging Role of Histone Deacetylase Inhibitors in WM".



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Session VII Novel Agents for Treatment of WM

Chairs: Dr. Dimopoulos (Greece) and Dr. Leblond (France)

1:30 PM	Dr. Buske (Germany)	CHOP vs. CHOP-R in WM.
1:45 PM	Dr. Rummel (Germany)	Bendamustine and Rituximab versus CHOP-R in WM.
2:00 PM	Dr. Ghobrial (USA)	Akt and MTOR inhibitors in WM.
2:15 PM	Dr. Grewal (USA)	Targeting CD70 in WM.
2:30 PM	Dr. Advani (USA)	Targeting CD40 in WM.
2:45 PM	Dr. Roccaro (USA)	Novel proteasome inhibitors in WM.
3:00 PM	Panel Discussion	All Session VII Speakers.
3:15-3:45 PM		Session Break and Refreshments.
3:45-4:15 PM		<u>Special Guest Lecturer:</u>
Dr. Anderson (USA)		"Applying the Lessons of MM Therapy to WM".

Consensus Panel Session I

Chairs: Dr. McMaster (USA) and Dr Pilarski (Canada)

4:15-6:00 PM		Basic and Translational Study Priorities in WM.
6:00 PM	Dr. Kimby (Sweden) Dr. Treon (USA)	Day Summary and Adjournment.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

**Friday, October 17, 2008 Nobel Museum, Gamla Stan (Old City)
Faculty and YIA Dinner Reception and Poster Presentations**

7:00-8:00 PM

Dinner Reception and YIA Recipient Poster Presentations

8:15 PM

Professor Anders Bárány (Sweden)

*Deputy Director of the Nobel Museum and Secretary of the Nobel Committee for
Physics of the Royal Swedish academy of Sciences.*

"History of Alfred Nobel and the Nobel Prize"

8:30 PM

Professor Ken Anderson (USA)

*Kraft Professor of Medicine, Harvard Medical School, Chief Hematologic Neoplasias,
Dana Farber Cancer Institute.*

Waldenström's Award Winner (2005)

"Are Innovations in Plasma Cell Disorders Worthy of a Nobel Prize?"

8:45 PM

Professor Bart Barlogie (USA)

Professor of Medicine, Head of Myeloma Institute, University of Arkansas.

Waldenström's Award Winner (1999)

"Is WM the next plasma cell disorder we should stop calling incurable?"

9:00 PM

Drs. Eva Kimby and Steve Treon (Sweden, USA)

Presentation of Young Investigator Awards

Closing Comments



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

2008 YIA Recipients

Poster 1: Xiaoying Jia (USA)

"The Novel Hydroxamic Acid-Derived HDAC Inhibitor, LBH589, Induces In Vitro Antitumor Activity in Waldenström's Macroglobulinemia"

Poster 2: Jenny Sun (USA)

"HDAC inhibitors : Epigenetic targeted therapies as monotherapy and combined treatments in WM"

Poster 3: Hai T. Ngo (USA)

"SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenström's macroglobulinemia"

Poster 4: Bénédicte Hivert (France)

"Acquired von Willebrand factor abnormalities in Waldenström's Macroglobulinemia"

Poster 5: Stéphanie Poulain (France)

"Is SDF1(-801 GA) polymorphism a new genetic prognostic for survival after treatment initiation in Waldenström's macroglobulinemia (WM)"

Poster 6: Laurent Vallat (France)

"Toward a Proteomic Specific Waldenström's macroglobulinemia Entity"

Poster 7: Thea Ioakimidis (USA)

"Comparative Outcomes following CP-R, CVP-R and CHOP-R in patients with Waldenström's Macroglobulinemia"

Poster 8: Stefan Peinert (Australia)

"Fludarabine based combinations are highly effective as first-line or salvage treatment for patients with Waldenström's Macroglobulinemia"



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Session X Disease-Related Morbidities in WM

Chairs: Dr. Merlini (Italy) and Dr. Stone (USA)

11:15 AM	Dr. Hochberg (USA)	Diagnosis and Management of Bing-Neel Syndrome.
11:30 AM	Dr. Nobile-Orazio (Italy)	Antigenic determinants of paraprotein related neuropathies in WM.
11:45 AM	Dr. Levine (USA)	Treatment of IgM related neuropathy.
12:00 PM	Dr. Ferman (France)	Cutaneous manifestations of WM.
12:15 PM	Dr. Berentsen (Norway)	Cold Agglutinin mediated AIHA in WM.
12:30 PM	Dr. Stone (USA)	Hyperviscosity Syndrome and Cryoglobulinemia.
12:45 PM	Dr. Menke (Switzerland)	Hyperviscosity related retinopathy in WM.
1:00 PM	Panel Discussions	All Session X Speakers.
1:30-2:30 PM		Session Break and Lunch.
2:00-2:30 PM	Dr. Merlini (Italy)	<u>Special Guest Speaker:</u> "Biology and Therapy of Amyloidosis associated with IgM monoclonal protein"

Consensus Panel Session II

Chairs: Dr. Dimopoulos (Greece) and Dr Treon (USA)

2:30-4:00 PM		Treatment Options and Clinical Trial Priorities in WM.
4:00 PM	Dr. Kimby (Sweden) Dr. Treon (USA)	Day Summary and Adjournment.



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

Saturday, October 18, 2008		Closing Ceremonies
Stockholm City Hall/Nobel Hall		
7:00 PM	Faculty and YIA Group Photo Session	Blue Room/Nobel Hall.
7:30 PM	Welcome Reception and Chorus Serenade	Golden Room Balcony.
8:00 PM	Dinner Reception	Golden Room/Nobel Hall.
8:15 PM	Mr. Bo Aurehl (Sweden)	History of the Nobel Hall.
8:30 PM	Dr. P. Bing (USA)	Former Chair, and Trustee, Stanford University.
8:40 PM	Mrs. Harriet Fulbright (USA)	Former Chair, U.S. National Endowment for Arts, Humanities; President, Fulbright Foundation. Tribute to Jan Waldenström.
9:00 PM	Dr. Kimby (Sweden)	
9:10 PM	Dr. A. Waldenström (Sweden)	
9:20 PM	Dr. U. Ringborg (Sweden)	
9:30 PM	Dr. G. Merlini (Italy)	
9:40 PM	Dr. Treon (USA)	Presentation of Waldenström Awards.
9:50 PM	Host Remarks	6 th International Workshop, 2010.
10:00 PM	Chairs Closing Remarks	



**5th International Workshop on
Waldenström's Macroglobulinemia
October 15-19, 2008
Stockholm, Sweden**

**Sunday, October 19, 2008 Sheraton Stockholm
IWMF European WM Patient and Physician Forum**

Moderators: Drs. Eva Kimby (Sweden) and Véronique LeBlond (France).

9:00 AM	Dr. Kyle (USA)	Diagnosis and Criteria to Treat WM.
9:30 AM	Dr. Treon (USA)	Consensus Recommendations for Treatment of WM.
10:00 AM	Dr. LeBlond (France)	Weighing Long Term Consequences in Treatment Decisions.
10:30 AM	Dr. Kimby (Sweden)	Response Criteria in WM.
10:30-12:00	All Session Speakers	Panel Discussions.
12:00-1:15 PM		Session Break and Luncheon.
1:15-2:00 PM	Ms. Lynn Paul (USA) Mr. Edward Saltzman (USA) Mrs. Karen Lee Sobol (USA)	Patient Guest Speakers
2:00-5:00 PM		U.S.-European IWMF Sponsored Patient Meeting

CME Accreditation.

The 5th International Workshop on Waldenström's Macroglobulinemia is accredited by EXCEL Continuing Education in conformance with the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and nurses. This activity is designated for a maximum of 29.00 AMA PRA Category 1 Credits. Physicians and nurses attending this event should only claim credit commensurate with the extent of their participation in the activity.

Disclosures.

In accordance with ACCME standards, all speakers were required to provide disclosure of affiliations and/or financial interests with commercial organizations involved with products to which they may refer to during their presentations. Presenters who have made a disclosure are as follows:

Kenneth C. Anderson, MD	Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Inc.
Bart Barlogie, MD, PhD	Celgene Corporation, Millennium: The Takeda Oncology Company.
Magnus Bjorkholm, MD	Shire, Wyeth Pharmaceuticals, Pfizer Inc.
Christian Buske, MD	Roche Pharmaceuticals.
Christine Chen, MD	Celgene Corporation, Ortho-Biotech.
Meletios Dimopoulos, MD	Roche Pharmaceuticals.
Morie Gertz, MD	Celgene Corporation, Millennium: The Takeda Oncology Company.
Irene Ghobrial, MD	Celgene Corporation, Millennium: The Takeda Oncology Company.
Douglas Joshua, MD	Janssen-Cilag, Celgene Corporation, Johnson & Johnson.
Robert A. Kyle, MD	Johnson & Johnson, Celgene Corporation, Millennium: The Takeda Oncology Company, Kosan Biosciences, Novartis Inc., Pharmion Corporation.
Todd Levine, MD	Forest Laboratories, Pfizer Inc., Eli Lilly & Company, GlaxoSmithKline.
Nikhil Munshi, MD	Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Inc.

Marvin Stone, MD, MACP	US Oncology.
Owen O'Connor, MD, PhD	Allos Therapeutics, Millennium: The Takeda Oncology Company, Merck & Company, Inc., Gloucester Pharmaceuticals. Inc., Proteolyx, TopoTarget, Abbot Laboratories, Cytokinetics, Merck & Company, Inc.
Steven P. Treon MD, PhD	Celgene Corporation, Millennium: The Takeda Oncology Company, Genentech Inc, Biogen IDEC Inc.

Unapproved or Investigational Uses of Drugs and Devices.

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the FDA and/or the EMA. Participants are encouraged to consult the approved product labeling for any drug or device mentioned in this activity before its use. The opinions expressed in the workshop presentations are those of the abstract authors and do not necessarily represent the opinions of the IWWM5.



The 5th International Workshop on Waldenström's macroglobulinemia (IWWM) is sponsored by the International Society for the Study of Waldenström's Macroglobulinemia. Proceedings of this conference can be found at www.wmworkshop.org and in the March 2009 edition of ***Clinical Lymphoma & Myeloma***. For further information on the IWWM, please contact:

Christopher Patterson
 Director- Bing Center for Waldenström's macroglobulinemia
 Dana Farber Cancer Institute
 44 Binney Street, M548
 Boston, MA 02115-6084
 617.632.6285

christopher_patterson@dfci.harvard.edu